Last reviewed · How we verify
full amount low molecular weight heparin
Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.
Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.
At a glance
| Generic name | full amount low molecular weight heparin |
|---|---|
| Also known as | Full amount enoxaparin |
| Sponsor | Beijing Anzhen Hospital |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); Factor Xa and Factor IIa (indirect targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller molecular fragments. These fragments bind to antithrombin III and potentiate its inhibition of factor Xa and thrombin (factor IIa), thereby preventing thrombus formation. LMWH has more predictable pharmacokinetics and bioavailability compared to unfractionated heparin, allowing for subcutaneous administration without routine monitoring.
Approved indications
- Thromboembolism prophylaxis in surgical patients
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: